BROOMFIELD, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (NASDAQ: ABIO), a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular disease, today announced, as required by NASDAQ Marketplace Rule 5810(b), that on March 12, 2010, it received a notice from the NASDAQ Stock Market indicating that the Company’s stockholders’ equity as of December 31, 2009, did not meet the minimum requirement of $10,000,000 for continued listing as set forth in Continued Listing Standards for Primary Equity Securities Rule 5450(b). This notification does not affect the listing of the Company’s common stock at this time.
